Ranbaxy Laboratories, the country's largest pharmaceutical company, today announced that the Medicines and Healthcare products Regulatory agency (MHRA) of the UK and the Therapeutic Goods Administration (TGA), Department of Health and Aging of the Australian government, have issued Good Manufacturing Practice (GMP) certificates for its manufacturing site at Paonta Sahib (India), following a joint audit conducted in October 2008.
The MHRA approval will not only cover product filings for the UK but will also apply to product filings for the entire European Union.
ALSO READ THE FOLLOWING STORIES :
Editorial: Lesson for Ranbaxy
Both authorities had inspected this facility in 2006 and had found it complaint with the respective principals and guidelines of GMP. GMP certificates valid up to 2 years were issued. Subsequent to the routine re-audit in November 2008 conducted by these authorities GMP certificates has been extended for 3 years by the MHRA and for 2 years by the TGA.
Ranbaxy serves customers in 125 countries. It has ground operations in 49 countries and manufacturing operations in 11 countries.